Nasopharyngeal carcinoma is a rare cancer in Western society, however there is a higher incidence in Asian, Chinese and African populations. A significant number of Asians reside in Australia, and consequently patients with nasopharyngeal carcinoma are an increasing clinical problem. Radiotherapy has been the predominant treatment in the past, but more recently multi-modality treatments have been utilised. The results of an Intergroup trial, coordinated by the Southwest Oncology Group (SWOG) demonstrated markedly superior progression free and overall survival for combined chemoradiotherapy compared to radiotherapy alone. At three years progression free survival was 24% for the radiotherapy arm and 69% for the chemoradiotherapy group (P < 0.001), and three-year survival was 47% for the radiotherapy arm compared with 78% for the combined arm (P = 0.005). There was minimum toxicity reported for either of the arms and no treatment related deaths. Based on these survival data the administration of concomitant cisplatin and radiotherapy has become standard of care for nasopharyngeal carcinoma in the USA. Our institution has also adopted a similar combined therapy protocol for patients with stage III and IV nasopharyngeal cancer and good performance status. The patients treated at our institution have experienced significant side effects. We describe the case of a woman so treated with this protocol who subsequently developed severe life threatening laryngeal necrosis.
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Key words: chemoradiotherapy, combined percutaneous enterogastrostomy, laryngeal infarction/necrosis, nasopharyngeal carcinoma, toxicity Case report A 47-year-old Iraqi woman presented in August 1997 with an eight-month history of left neck swelling. Subsequent investigations revealed a T\N^ undifferentiated large-cell carcinoma arising from the nasopharynx ( Figure 1 , CT scans; Figure 2 , Histopathology). The patient had no significant past medical history, and was a life long non smoker and non drinker. She was on no regular medications and had no known allergies.
Clinical examination revealed a large left submandibular mass and pathological fixed left cervical lymph nodes measuring 8-10 cm. There were no other significant clinical findings. The ECOG performance status was 0. The patient agreed to be treated with combined chemoradiotherapy, but due to a delay in commencing radiotherapy she was treated initially with chemotherapy alone and received three cycles of cisplatin 100 mg on day 1 and 5-fluorouracil (5-FU) 1250 mg days 1-4 every three weeks. A central venous catheter was inserted prior to the second cycle due to poor venous access. The patient completed three cycles of chemotherapy with the principal toxicity being grade 3 nausea and vomiting. A partial response was achieved in the cervical lymph nodes.
Combined chemoradiotherapy commenced according to the Intergroup protocol [1] . The patient received 66 Gy in 33 fractions to the isodose covering the tumour and 50 Gy in 25 fractions to the supraclavicular lymph nodes and lower neck. Because of the large tumour mass, particularly the neck disease which was slow to respond to initial treatment, the boost fields were larger than normal. The vocal cords were not in the boost area, however the supraglottic region received 10% more than the prescribed dose, 73 Gy in 33 fractions because of contour variation. On day 17 the patient was admitted to hospital for management of grade 4 nausea, vomiting, and dehydration. Day 43 cisplatin was omitted due to ongoing problems managing nausea and vomiting. At the completion of the treatment the patient was reporting significant problems with lethargy, mucositis, and a marked localised skin reaction in the radiotherapy fields. The patient presented six weeks after completing combined treatment with persistent dysphagia, hoarse voice, stridor, and was admitted to the Intensive Care Unit. Nasal endoscopy revealed a swollen erythematous supraglottis, with no evidence of recurrent tumour. The patient's condition improved slowly and discharge occurred after two weeks. Three weeks later she was readmitted with dysphagia, weight loss and coughing following meals. A modified barium swallow confirmed pulmonary aspiration and an ENT review again revealed moderate supraglottic swelling, and no evidence of recurrent tumour. A percutaneous enterogastrostomy feeding tube (PEG) was inserted. The patient represented acutely to the emergency department three weeks later with a six-hour history of stridor, inability to talk and difficulty breathing. An emergency cricothyroidotomy with a minitrach was performed and a nasal endotrachael tube was later inserted via direct laryngoscopy and she was admitted to the Intensive Care Unit. The next day a microlarynoscopy demonstated gross glottic and supraglottic swelling. There were deep mucosal ulcerations with arytenoid cartilage exposure, but no evidence of residual malignancy and a tracheostomy was performed. The hospitalisation was complicated by aspiration pneumonia. Final discharge home occurred after four weeks hospitalisation with a tracheostomy, a PEG feeding tube in situ and the patient requiring regular oral morphine for analgesia. A course of hyperbaric oxygen treatment was commenced to encourage healing of the laryngeal ulceration. At her most recent follow-up on 10 March 1999 her neck was substantially less swollen, but remained very firm. There was marked trismus, laryngeal fixation and a reduction in neck movement. Direct laryngoscopy has been very difficult even with a paediatric rigid bronchoscope, but demonstrated fixated arytenoids, with the left arytenoid partially absent and a posterior glottic web. There was again no evidence of recurrence. The patient remains tracheostomy dependent and is likely to remain this way long term. She is also being assessed for conditions which might predispose to excessive radiation toxicity.
This case illustrates a severe, life threatening complication following combined modality treatment for nasopharyngeal cancer. We feel it is important to alert other oncology units, who may likewise be encouraged by the Intergroup trial results, that whilst there is a major survival advantage with combined modality treatment, toxicity should not be underestimated. We have treated 13 patients with nasopharyngeal carcinoma according to the Intergroup guidelines and to date have achieved a complete response in all patients, however the toxic complicami tions have been a significant problem. The main side effects have been mucositis, dysphagia, and marked weight loss. All patients have required admission to hospital for control of these complications which have neccesitated insertion of PEG feeding tube enabling adequate nutrition. Our other concern is the potential for long term side effects, which are obviously too early to assess.
Overview on the treatment of nasopharyngeal carcinoma and treatment associated toxicity
The aim of treating patients with nasopharyngeal carcinoma is to achieve a cure, except when the disease is metastatic at presentation. Radiotherapy has been the primary treatment for locally and regionally confined stages. Surgery has a limited role due to the complex anatomical location of the tumour and the propensity for metastasis. The outcome from single modality radiotherapy has improved over the decades following the appreciation that bulky disease requires higher doses of radiotherapy, advances in radiological imaging allowing accurate targeting of the primary tumour, and the use of higher energy sources. The overall five-year survival rates following definitive radiotherapy are stage dependent and range from 70%-80% for stage I, to 20%-40% for stage IV. Most recurrences are observed in the first two years after therapy.
Patients with locoregionally advanced disease, which includes large tumours (T 3 or T 4 ) or nodal involvement (Ni_ 3 ), but no systemic metastases have traditionally been treated with radiotherapy, however many patients relapse and long-term survival rates are poor. Nasopharyngeal carcinoma has a higher propensity to metastasise than other head and neck cancers, although locoregional relapse still represents a significant proportion of treatment failures. Isolated local and/or regional failures after definitive radiotherapy occur in 30%-60% of patients. This has been the rationale behind the addition of chemotherapy to radiotherapy, either sequentially or concurrently. Induction chemotherapy aims to eradicate potential microscopic metastatic disease and reduce the primary tumour burden in the nasopharynx prior to radiotherapy. Concurrent chemoradiotherapy, as well as eradicating potential distant disease, enhances the cytotoxicity of the radiation.
Trials of induction chemotherapy have shown promise in improving tumour control and possibly survival, however results from different groups are conflicting.
In 1996 the International Nasopharynx Cancer Study Group (VUMCA I Trial) published preliminary results of a phase III trial comparing neoadjuvant chemotherapy plus radiotherapy to radiotherapy alone in patients with nasopharyngeal carcinoma (any T, N 0, 1 or 2, M o ) showing a significant disease free survival in the chemotherapy group, although with no significant difference in overall survival between the two arms [2] . There was a significant difference between the treatment related mortality, with more patients dying on the chemotherapy arm. The authors suggested that longer follow-up may be required to detect a difference in overall survival between the two groups.
The M.D. Anderson Cancer Centre reviewed its results with definitive radiotherapy for carcinoma of the nasopharynx in 1997 and concluded that very good long term local and regional control rates are achieved, with a reduction in the frequency of severe late complications resulting from improved treatment techniques. They identified a sub-group of patients with poor prognostic characteristics, namely advanced tumour stage at diagnosis with poorly differentiated carcinoma histology, as candidates for dose escalation or combined modality studies [3] .
The role of concomitant chemoradiotherapy has become standard practise in the United States following the results of the Intergroup trial outlined above. One concern about the widespread adoption of this form of treatment is the limited knowledge of long term side effects.
The acute and long-term toxicities from radiotherapy to the nasopharynx have been extensively studied [6] . Acutely the main toxicity involves mucositis, xerostomia and dysphagia which occur in virtually all treated patients, to a varying degree. Sanguined et al. in their retrospective review of radiotherapy management of nasopharyngeal carcinoma reported the incidence of late complications as 16%, 19%, and 29% at 5, 10 and 20 years [3] . Using the RTOG grading system 85% experienced grade 2 or less complications, 12% grade 3 or 4 and 3% died of late complications. The incidence of severe late complications decreased over the treatment period, most likely due to modifications in the treatment technique. The long-term reported side effects included accelerated dental decay and caries, neck fibrosis, trismus and rarely osteoradionecrosis. Cranial nerve palsies occurred in \%-5% patients. Transverse myelitis which was previously a complication of radiotherapy is now avoided with modern planning techniques. Endocrine failure due to irradiation of the hypothalamus-pituitary axis and thyroid gland is also occasionally documented. Laryngeal necrosis which developed in this patient, three and half months after completing combined therapy has not been previously reported. The enhanced radiosensitisation provided by chemotherapy, as well as increasing the chance of cure, obviously has the potential to increase any toxicity caused by irradiation. Our patient received a slightly larger dose of boost radiation to the supraglottic are due to the bulky nature of her disease and the suboptimal response of her neck disease to initial chemotherapy. However as this method of treatment is being widely adopted awareness of this potential and life-threatening complication is important.
